Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Pfizer's Ibrance (palbociclib) wins FDA label expansion for HR-positive, HER2-positive metastatic breast cancer based on Ph3 data
Small molecule, cancer, CDK4/6 inhibitor, breast cancer, HER2-positive, combination therapy - Read more

NICE recommends MSD's Keytruda (pembrolizumab) with chemoradiotherapy for Ph3-backed locally advanced cervical cancer
Antibody, cancer, monoclonal antibody, cervical cancer, PD-1 inhibitor, combination therapy - Read more

FDA approves Gilead's Trodelvy (sacituzumab govitecan) and Merck & Co.'s Keytruda combo for first-line triple-negative breast cancer
Antibody-drug conjugate, cancer, triple-negative breast cancer, TROP-2, combination therapy, PD-L1 - Read more

FDA approves Ionis Pharmaceuticals' Tryngolza (olezarsen) label expansion for severe hypertriglyceridemia following Ph3 success
Antisense oligonucleotide, metabolic, small molecule, hypertriglyceridemia, apolipoprotein C-III, pancreatitis - Read more

Boehringer Ingelheim, Immunai partner on AI-driven T-cell target discovery for cancer and autoimmune diseases, up to $15M
Research collaboration, oncology, autoimmune, AI/ML, drug discovery, milestone payments - Read more

Ionis Pharmaceuticals, Recordati strike ex-US licensing deal for zilganersen, $30M upfront plus tiered royalties
Licensing deal, rare disease, neurological, antisense oligonucleotide, milestone payments, royalties - Read more

NurExone Biologic, ExoLyra sign binding MOU for naïve exosome distribution in Mexico
Distribution agreement, exosome therapy, regenerative medicine, commercialization, milestone payments - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Otsuka's (centanafadine) Ph3b trial succeeds in adults with attention-deficit/hyperactivity disorder and comorbid anxiety
Small molecule, neurological, ADHD, reuptake inhibitor, comorbid anxiety - Read more

HUTCHMED's (fanregratinib) Ph2 data presented at ESMO GI, supporting NMPA priority review for FGFR2-fusion intrahepatic cholangiocarcinoma
Small molecule, cancer, FGFR inhibitor, cholangiocarcinoma, FGFR2 fusion - Read more

Parexel launches biotech incubator, partners with Cape Fear BioCapital to support early-stage therapeutics companies
Biotech incubator, early-stage therapeutics, clinical development, regulatory strategy, venture capital - Read more

Absci prices $100M underwritten offering, advancing AI-designed anti-PRLR antibody program
Generative AI, antibody, clinical-stage, dermatology, endometriosis - Read more

eXoZymes awarded $2M NIH SBIR grant to advance cannabinoid analogs for drug discovery
Cell-free platform, drug discovery, cannabinoids, small molecule, preclinical - Read more

Oblenio Bio raises $62M Series B, advancing tri-specific autoimmune T-cell engager to trials
Autoimmune, T-cell engager, tri-specific, preclinical, B-cell depletion - Read more

Anodyne Nanotech closes $12.6M Series A to advance once-weekly GLP-1 obesity patch
Transdermal delivery, obesity, GLP-1, peptide therapeutics, clinical-stage, platform technology - Read more

Merck KGaA to acquire Bio-Techne Corporation for $11.3B in largest deal since 2015 Sigma-Aldrich purchase
Life sciences tools, strategic, major transaction - Read more

Remix Therapeutics goes public via reverse merger with Passage Bio, raising $100M in private financing
Small molecule, oncology, major transaction, strategic - Read more

FDA hiring 2,200 staff to rebuild workforce after DOGE cuts eliminated 3,000 employees
FDA, regulatory affairs, operational, workforce - Read more

BIO CEO Crowley, DOD's Overton emerge as top FDA commissioner candidates per RBC analysis
Rare disease, regulatory, strategic - Read more

REGENXBIO plans accelerated approval BLA filing for Duchenne gene therapy RGX-202 amid shifting FDA stance
Gene therapy, rare disease, regulatory, accelerated approval - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA flags Pinnacle Biologics for misleading Photofrin videos that obscure cancer drug indications
Photodynamic therapy, oncology, regulatory, operational - Read more

FDA issues warning letter to Jubilant HollisterStier over mold investigation delays and quality unit failures
Contract manufacturing, sterile manufacturing, operational, quality compliance - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here